NCT02967159View on ClinicalTrials.gov

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 24, 2016

Primary Completion Date

April 6, 2017

Study Completion Date

April 6, 2017

Conditions
Chronic Obstructive Pulmonary Disease (COPD)Asthma
Interventions
DRUG

Abediterol

Treatment A: Abediterol 2.5 μg via DPI

DRUG

AZD7594

Treatment B: AZD7594 440 μg via DPI

DRUG

AZD7594/abediterol

Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI

DRUG

AZD7594 and abediterol

Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY